BR112023022705A2 - Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares - Google Patents
Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças ocularesInfo
- Publication number
- BR112023022705A2 BR112023022705A2 BR112023022705A BR112023022705A BR112023022705A2 BR 112023022705 A2 BR112023022705 A2 BR 112023022705A2 BR 112023022705 A BR112023022705 A BR 112023022705A BR 112023022705 A BR112023022705 A BR 112023022705A BR 112023022705 A2 BR112023022705 A2 BR 112023022705A2
- Authority
- BR
- Brazil
- Prior art keywords
- intravitrual
- treatment
- pharmaceutical compositions
- drug delivery
- delivery systems
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182559P | 2021-04-30 | 2021-04-30 | |
| US202163287737P | 2021-12-09 | 2021-12-09 | |
| PCT/US2022/027048 WO2022232588A1 (en) | 2021-04-30 | 2022-04-29 | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022705A2 true BR112023022705A2 (pt) | 2024-01-16 |
Family
ID=83848732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022705A BR112023022705A2 (pt) | 2021-04-30 | 2022-04-29 | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11786510B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4329753A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024515826A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240004643A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022264036A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023022705A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218251A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307997A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012723A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022232588A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7664239B2 (ja) | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| BR112023022705A2 (pt) * | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
| CN117295520A (zh) * | 2021-04-30 | 2023-12-26 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
| WO2025137005A1 (en) * | 2023-12-20 | 2025-06-26 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
| AU2024405327A1 (en) * | 2023-12-20 | 2026-07-02 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4282793A (en) | 1992-04-10 | 1993-11-18 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US6573285B2 (en) * | 2000-12-21 | 2003-06-03 | Bristol-Myers Squibb Co. | Method for preventing or treating pain by administering an endothelin antagonist |
| CZ20032350A3 (en) | 2001-02-02 | 2004-03-17 | Merck Patent Gmbh | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS |
| US20030176356A1 (en) | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| PL2424530T3 (pl) | 2009-04-30 | 2016-07-29 | Univ Midwestern | Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej |
| US20110082151A1 (en) | 2009-06-12 | 2011-04-07 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| AR080888A1 (es) | 2010-04-12 | 2012-05-16 | R Tech Ueno Ltd | Uso de un derivado de acido graso para producir una composicion oftalmica |
| EP2956096A1 (en) | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
| EP4046628A1 (en) | 2013-10-31 | 2022-08-24 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| ES2813383T3 (es) | 2013-12-19 | 2021-03-23 | Tassos Georgiou | Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso |
| ES2584534B1 (es) | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| JP2018522942A (ja) * | 2015-05-29 | 2018-08-16 | エッジ セラピューティクス インコーポレイテッド | 視力障害を低減するための組成物及び方法 |
| CN115337254A (zh) | 2015-07-23 | 2022-11-15 | 爱瑞制药公司 | 用于治疗眼病的玻璃体内药物递送系统 |
| WO2017217967A1 (en) | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| US10905770B2 (en) * | 2017-07-17 | 2021-02-02 | Macregen, Inc. | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases |
| WO2019210194A1 (en) | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| CA3132635A1 (en) | 2019-03-05 | 2020-09-10 | Aerie Pharmaceuticals, Inc. | Pharmaceutical compositions for treating ocular diseases or disorders |
| KR102191180B1 (ko) * | 2019-05-31 | 2020-12-15 | 삼진제약주식회사 | 안질환 치료용 조성물 |
| JP7664239B2 (ja) * | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| CN117295520A (zh) * | 2021-04-30 | 2023-12-26 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
| BR112023022705A2 (pt) * | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
-
2022
- 2022-04-29 BR BR112023022705A patent/BR112023022705A2/pt unknown
- 2022-04-29 IL IL307997A patent/IL307997A/en unknown
- 2022-04-29 WO PCT/US2022/027048 patent/WO2022232588A1/en not_active Ceased
- 2022-04-29 EP EP22796857.5A patent/EP4329753A4/en active Pending
- 2022-04-29 KR KR1020237040742A patent/KR20240004643A/ko active Pending
- 2022-04-29 MX MX2023012723A patent/MX2023012723A/es unknown
- 2022-04-29 AU AU2022264036A patent/AU2022264036A1/en active Pending
- 2022-04-29 JP JP2023566511A patent/JP2024515826A/ja active Pending
- 2022-04-29 CA CA3218251A patent/CA3218251A1/en active Pending
- 2022-11-30 US US18/060,503 patent/US11786510B2/en active Active
-
2023
- 2023-09-07 US US18/463,102 patent/US12622894B2/en active Active
-
2025
- 2025-06-09 US US19/232,649 patent/US20260130890A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL307997A (en) | 2023-12-01 |
| US20260130890A1 (en) | 2026-05-14 |
| MX2023012723A (es) | 2024-02-08 |
| KR20240004643A (ko) | 2024-01-11 |
| US11786510B2 (en) | 2023-10-17 |
| US20230105507A1 (en) | 2023-04-06 |
| US12622894B2 (en) | 2026-05-12 |
| CA3218251A1 (en) | 2022-11-03 |
| JP2024515826A (ja) | 2024-04-10 |
| WO2022232588A1 (en) | 2022-11-03 |
| AU2022264036A1 (en) | 2023-11-23 |
| US20230414577A1 (en) | 2023-12-28 |
| EP4329753A1 (en) | 2024-03-06 |
| EP4329753A4 (en) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012723A (es) | Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares. | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| CA2909160C (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| MX2023005533A (es) | Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. | |
| WO2011106702A3 (en) | Sustained delivery of therapeutic agents to an eye compartment | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| EA202191684A1 (ru) | Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии | |
| US10279046B2 (en) | Eye drop composition for treating ocular inflammatory disease and preparation method therefor | |
| CN101332180A (zh) | 霉酚酸滴眼剂及其制备方法 | |
| RU2545798C1 (ru) | Фармацевтическая композиция для оказания первой медицинской помощи при ожогах различной этиологии, площади и глубины в форме спрея, геля, аэрозоля | |
| ZA202106768B (en) | Triamterene or nolatrexed for use in the treatment of phenylketonuria | |
| RU2416394C1 (ru) | Фармацевтическая композиция в виде спрея для лечения раневых поверхностей | |
| MX2025007776A (es) | Conjugados de farmaco para el tratamiento de trastornos oculares | |
| CA3113929C (en) | Use of miltefosine for treating free-living amoebic infections | |
| KR20200143630A (ko) | 히알루론산 기반의 안과용 약물전달체 | |
| US20200316075A1 (en) | Ganciclovir compositions and related methods | |
| BR112022001620A2 (pt) | Composto, processo para preparar um composto, composição farmacêutica e conjugado anticorpo-droga | |
| WO2014204357A3 (ru) | Лекарственное средство для лечения кератоконуса | |
| RU2475248C1 (ru) | Офтальмологическое средство-2 для кросслинкинга | |
| CN116251169A (zh) | 达托霉素滴眼液、其制备方法及应用 | |
| TWI590827B (zh) | 以組合透明質酸及黃素腺嘌呤二核苷酸為特徵的角膜上皮細胞死亡抑制劑 | |
| BR112023021049A2 (pt) | Uso de adenina na fabricação de um medicamento para tratamento de úlcera diabética | |
| RU2008126108A (ru) | Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту | |
| RU2419417C1 (ru) | Фармацевтическая композиция в виде раствора флуконазола, обладающая противогрибковым действием |